国际医学
(000516)
| 流通市值：100.93亿 | | | 总市值：102.99亿 |
| 流通股本：21.94亿 | | | 总股本：22.39亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 375,229,992.66 | 411,435,027.78 | 331,072,769.68 | 397,812,399.82 |
| 交易性金融资产 | 11,096,670 | 12,916,124 | 13,795,860 | 15,335,398 |
| 应收票据及应收账款 | 455,523,010.89 | 518,618,735.33 | 616,881,093.77 | 594,164,437.89 |
| 应收账款 | 455,523,010.89 | 518,618,735.33 | 616,881,093.77 | 594,164,437.89 |
| 预付款项 | 15,180,206.08 | 14,471,712.15 | 19,114,837.65 | 18,838,552.95 |
| 其他应收款合计 | 24,096,449.9 | 18,047,454.3 | 49,289,410.59 | 51,589,526.23 |
| 存货 | 58,681,866.73 | 67,228,916.46 | 75,274,149 | 60,881,548.14 |
| 合同资产 | 58,349,619.83 | 45,564,423.05 | - | - |
| 其他流动资产 | 43,731,455.9 | 43,124,314.1 | 45,439,576.11 | 47,331,265.59 |
| 流动资产合计 | 1,041,889,271.99 | 1,131,406,707.17 | 1,150,867,696.8 | 1,185,953,128.62 |
| 非流动资产: | | | | |
| 长期股权投资 | 1,581,474.13 | 1,982,043.37 | 1,513,962.51 | 1,708,984.08 |
| 其他非流动金融资产 | 246,382,113.29 | 246,605,482.66 | 245,822,813.43 | 253,192,182.01 |
| 投资性房地产 | 15,158,637.87 | 15,406,748.37 | 15,654,858.87 | 15,902,969.37 |
| 固定资产 | 7,281,199,736.41 | 6,701,045,620.17 | 6,838,102,473.27 | 6,968,701,386.18 |
| 在建工程 | 92,771,967.79 | 737,294,480.54 | 344,317,451.56 | 359,639,390.88 |
| 无形资产 | 674,776,769.05 | 680,052,931.43 | 684,750,146.68 | 692,901,964.68 |
| 长期待摊费用 | 35,459,131.83 | 39,365,224.87 | 44,585,004.84 | 45,588,986.11 |
| 递延所得税资产 | 66,808,214.72 | 66,878,771.83 | 71,976,312.29 | 78,827,188.71 |
| 其他非流动资产 | 41,413,405.75 | 91,015,373.79 | 393,065,792.64 | 403,095,491.48 |
| 非流动资产合计 | 8,455,551,450.84 | 8,579,646,677.03 | 8,639,788,816.09 | 8,819,558,543.5 |
| 资产总计 | 9,497,440,722.83 | 9,711,053,384.2 | 9,790,656,512.89 | 10,005,511,672.12 |
| 流动负债: | | | | |
| 短期借款 | 1,105,699,468.76 | 1,038,863,091.09 | 994,775,888.9 | 882,326,750.01 |
| 应付票据及应付账款 | 1,733,285,592.65 | 1,734,047,776.06 | 1,696,993,740.4 | 1,738,655,943.97 |
| 其中：应付票据 | 32,400,000 | 22,300,000 | 46,000,000 | 90,000,000 |
| 应付账款 | 1,700,885,592.65 | 1,711,747,776.06 | 1,650,993,740.4 | 1,648,655,943.97 |
| 预收款项 | 523,023.13 | 410,069.25 | 190,207.71 | 209,366.69 |
| 合同负债 | 241,099,096.79 | 238,285,859.96 | 230,420,758.31 | 234,309,292.72 |
| 应付职工薪酬 | 125,752,879.99 | 182,720,613.45 | 165,579,602.55 | 152,683,209.9 |
| 应交税费 | 21,083,238.4 | 23,523,181.64 | 23,718,782.18 | 24,831,076.71 |
| 其他应付款合计 | 140,690,714.85 | 218,207,164.58 | 212,841,791.75 | 179,799,928.87 |
| 应付股利 | 1,209,363.18 | 1,209,363.18 | 1,209,363.18 | 1,209,363.18 |
| 一年内到期的非流动负债 | 848,893,912.78 | 1,016,560,714.49 | 905,070,397.04 | 997,942,636.01 |
| 其他流动负债 | 5,444.39 | 5,019.58 | 5,137.18 | 5,551.33 |
| 流动负债合计 | 4,217,033,371.74 | 4,452,623,490.1 | 4,229,596,306.02 | 4,210,763,756.21 |
| 非流动负债: | | | | |
| 长期借款 | 2,120,791,815.73 | 2,168,680,149.04 | 2,493,642,911.24 | 2,570,997,911.21 |
| 长期应付款 | 209,090,704.18 | 67,256,762.48 | 99,597 | 99,597 |
| 预计负债 | 9,206,367.27 | 7,413,338.39 | 5,702,185.66 | 6,194,203.53 |
| 递延收益 | 5,002,129.47 | 5,091,429.85 | 4,945,171.12 | 5,080,224.72 |
| 递延所得税负债 | 2,715,896.55 | 2,715,896.55 | 2,400,000 | 2,400,000 |
| 非流动负债合计 | 2,346,806,913.2 | 2,251,157,576.31 | 2,506,789,865.02 | 2,584,771,936.46 |
| 负债合计 | 6,563,840,284.94 | 6,703,781,066.41 | 6,736,386,171.04 | 6,795,535,692.67 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 2,238,896,753 | 2,238,896,753 | 2,238,896,753 | 2,238,896,753 |
| 资本公积 | 971,666,482.14 | 971,666,482.14 | 971,666,482.14 | 971,655,974 |
| 盈余公积 | 400,702,384.75 | 400,702,384.75 | 400,702,384.75 | 400,702,384.75 |
| 未分配利润 | -341,445,393.03 | -293,103,843.55 | -273,684,991.31 | -144,990,278.39 |
| 归属于母公司股东权益合计 | 3,269,820,226.86 | 3,318,161,776.34 | 3,337,580,628.58 | 3,466,264,833.36 |
| 少数股东权益 | -336,219,788.97 | -310,889,458.55 | -283,310,286.73 | -256,288,853.91 |
| 股东权益合计 | 2,933,600,437.89 | 3,007,272,317.79 | 3,054,270,341.85 | 3,209,975,979.45 |
| 负债和股东权益合计 | 9,497,440,722.83 | 9,711,053,384.2 | 9,790,656,512.89 | 10,005,511,672.12 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-30 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |